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ABSTRACT
Thyroid stimulating hormone (TSH) is a cancer growth stimulus factor that have 
effect on the progression of thyroid carcinoma, common neck head malignancy. 
This hormonelevel has diagnostic value and can assist in the diagnosis, staging 
and management of the thyroid carcinoma. This study aimed to investigatethe 
role of TSH level as a predictor of advance stage thyroid carcinoma. This was 
case-control study involvingthyroid enlargement subjects who underwent 
thyroidectomy at Dr. Sardjito General Hospital, Yogyakarta from 2015 to 2017. 
Cancer staging examination using AJCC 2102 and TSH levels examination were 
conducted before underwent thyroidectomy. The inclusion criteria for case 
group were advanced stage (stage III and IV), while for control group wereearly-
stage of thyroid carcinoma (stage I and II). The exclusion criteria for both case 
and control groups were 1) suffering from thyroid hormone disorders requiring 
therapy before thyroidectomy, 2) receiving thyroid suppression therapy prior 
to thyroidectomy. Sixty-six post thyroidectomy patients were involved in this 
study. The patients were divided into case and control groups consisted of 33 
patients in each group. Based on receiver operating characteristic curve, the 
cut of point 1.27 mIU/L for TSH was obtained with sensitivity of 72.7% and 
specificity of 78.8%. There was statistically significant difference TSH levels 
between early stage thyroid carcinoma and late stage thyroid carcinoma (p = 
0.001;OR: 9.9;95% CI: 3.19-30.15). It can be concluded that TSHlevels ≥ 1.27mIU/L 
as predictor of advance stage thyroid carcinoma.
ABSTRAK
Hormon perangsang tiroid (thyroid stimulating hormone/TSH) adalah faktor 
stimulus pertumbuhan kanker yang berpengaruh terhadapp progresivitas 
kanker tiroid, keganasan kepala leher yang sering terjadi. Nilai kadar hormon 
ini penting dalam membantu penegakan diagnosis, penentuan stadium dan 
tatalaksana karsinoma tiroid. Tujuan penelitian ini adalah mengkaji peran 
kadar TSH sebagai prediktor karsinoma tiroid stadium lanjut. Penelitian ini 
merupakan penelitian potong lintang yang melibatkan pasien karsinoma tiroid 
yang menjalani operasi tiroidektomi di RSUP Dr. Sardjito, Yogyakarta dari tahun 
2015 sampai 2017. Pemeriksaan stadium karsioma dengan  AJCC 2012 dan 
pemeriksaan kadar TSH dilakukan sebelum menjalani tiroidektomi. Kriteria 
inklusi kelompok kasus adalah karsinoma tiroid stadium lanjut (stadium III 
dan IV), sedangkan kelompok kontrol adalah stadium awal (I dan II). Kriteria 
eksklusi kedua kelompok kasus dan kontrol adalah 1) menderita gangguan 
hormon tiroid yang membutuhkan terapi sebelum tiroidektomi, 2) menerima 
terapi penekanan tiroid sebelum tiroidektomi. Enam puluh enam pasien pasca 
tiroidektomi terlibat dalam penelitian. Pasien dibagi menjadi kelompok kasus 
dan kontrol dengan setiap kelompok 33 pasien. Berdasarkan receiver operating 
characteristic curve, diperoleh nilai ambang batas kadar TSH 1,27 mIU/L dengan 
sensitivitas 72,7% dan spesivisitas 78,8%. Terdapat perbedaan nyata kadar TSH 
antara karsinoma tiroid stadium awal dan karsinoma tiroid stadium akhir (p 
= 0,001; OR: 9,9; 95% CI: 3,19-30,15). Dapat disimpulkan bahwa kadar TSH ≥ 
1.27mIU/L merupakan prediktor karsinoma tiroid stadium lanjut.
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INTRODUCTION
Thyroid carcinoma is derived from 
two types of cells found in the thyroid 
gland. Follicular cells developing from 
endodermal can develop into papillary 
and follicular carcinomas. Cells 
derived from neuroendocrine-derived 
calcitonin-producing C cells can progress 
to medullary thyroid carcinoma. 
Thyroid lymphoma develops from the 
lymphoid tissue found in the thyroid 
tissue, while thyroid sarcoma originates 
from the connective tissue present in 
the thyroid.1 Histopathological thyroid 
carcinoma classified as 78% papillary 
type, 13% follicular type, 2% anaplastic 
type and 4% medullary type.2,3
Thyroid cancer represents about 1% 
of new cancer diagnoses or 23,500 cases 
in the United States each year. Thyroid 
malignancy is divided into papillary 
carcinoma (80%), follicular carcinoma 
(10%), medullary thyroid carcinoma 
(5-10%), anaplastic carcinoma (1-2%), 
primary thyroid lymphoma (rare), and 
primary thyroid sarcoma (very rarely). 
Approximately 7-15% of thyroid nodules 
are malignant. Other disorders include 
various benign diagnoses, including 
colloid nodules, degenerative cysts, 
hyperplasia, thyroiditis, or benign 
neoplasms.4 Incidence of disease is 
higher in women than men. A study 
conducted by Weir et al. from the Centers 
for Disease Control and Prevention 
(CDC), estimates that by the year 2020 
the highest cancer incidence in women 
is one of them is thyroid carcinoma.5
Thyroid papillary carcinoma is 
the most common type of thyroid 
carcinoma. This type of carcinoma is 
80% of the thyroid malignancy. Papillary 
carcinoma and follicular carcinoma are 
a differentiated carcinoma. Papillary 
carcinoma is a type of tumor with 
relatively slow growth. This tumor is 
derived from follicular cells that produce 
thyroxine (T4) and thyroglobulin (Tg) in 
the thyroid gland.6
The growth and development of 
thyroid carcinoma is influenced by 
oncogenes and various growth factors. 
Thyroid stimulating hormone (TSH) 
is a stimulus for cancer growth. This 
hypothesis is supported by the increased 
survival of patients with thyroid 
carcinoma treated with suppressive 
levothyroxine dose.6,7 Itis known as a 
growth factor of thyroid carcinoma and 
plays an important role in the growth and 
progression of thyroid carcinoma. The 
TSH levels above the average population 
levels will generally increase the risk of 
malignancy of the thyroid gland.Thyroid 
stimulating hormone has a role in the 
process of carcinogenesis, although 
there are still some differences in views 
from some researchers. Some experts 
concluded that TSH receptor stimulation 
is associated with increased incidence 
of cancer and aggressiveness. Mutations 
in TSH receptors will affect the cAMP 
activation pathway (cyclic adenosine 
monophosphate) via Gαs. The fact that 
higher levels of TSH are significantly 
associated with increased risk of 
malignancy is strong evidence that TSH 
receptor stimulation is associated with 
thyroid carcinoma.6
Based on the above data it can be 
estimated that TSH, known as thyroid 
growth factor, also provides an important 
role in the growth, development and 
progression of thyroid carcinoma. The 
diagnostic value of TSH can be used 
to help determine the likelihood of 
stages of thyroid carcinoma, so that the 
management of thyroid nodules can be 
performed more optimally. The aim of 
this research was to investigate the cut 
of point TSH levels and contribution 
of others variable to advanced stage 
thyroid carcinoma.
MATERIALS AND METHODS
This was an observational analytic 
case-control study to determine the 
differences in TSH levels of patients with 
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early and advanced thyroid carcinoma 
undergoing thyroidectomy. The study 
was started after receiving approval 
from the Medical and Health Research 
Ethics Committee (MHREC) Faculty of 
Medicine, Public Health and Nursing, 
Universitas Gadjah Mada, Yogyakarta 
(Ref. KE/FK/0494/EC/2018).
The study was performed from 
2015 until 2017 on patients who had 
been diagnosed thyroid carcinoma 
based on histopathologic examination.
The blood TSH levels were measured at 
least one week before thyroidectomy. 
High and low TSH levels were one of 
variables that affect early and advanced 
stage of thyroid carcinoma. The target 
population in this study were patients 
with thyroid carcinoma who underwent 
thyroidectomy. Affordable populations 
were thyroid carcinoma patients who 
undergo thyroidectomy at Dr. Sardjito 
General, Yogyakarta during 2015-
2017 until the number of samples was 
fulfilled. The sample of the study was 
thyroid carcinoma patients undergoing 
thyroidectomy at Dr. Sardjito General 
Hospital, Yogyakarta in 2015-2017 until 
fulfilled number of samples that meet 
the criteria of inclusion and exclusion.
Population and samples
The inclusion criteria for case 
group were 1) patients post-operative 
anatomical pathology examination 
results of the diagnosis of thyroid 
carcinoma; 2) advanced stage of thyroid 
carcinoma (stage III and IV). While the 
inclusion criteria for control group 
were 1) patients with post-operative 
anatomical pathology examination 
results for the diagnosis of thyroid 
carcinoma; 2) early-stage of thyroid 
carcinoma (stage I and II). The exclusion 
criteria for case and control groups 
were 1) patients suffering from thyroid 
hormone disorders requiring therapy 
before thyroidectomy; 2) patients 
receiving thyroid suppression therapy 
prior to thyroidectomy. The sample of 
this research was thyroid enlargement 
patient in Dr. Sardjito General Hospital, 
Yogyakarta, which was calculated by the 
difference proportion formula, α:5%; 
β:20%, total sample were 66, that was 33 
samples each group.
Statistical analysis
Differences in the proportion of 
the TSH levels between differentiated 
thyroid carcinoma groups and benign 
thyroid enlargement were analyzed 
using Chi square test, and then calculated 
the odds ratio (OR) and multivariate 
analysis. The cut-off point of TSH levels 
was determined using receiver operating 
characteristic (ROC) curve analysis. 
A p value < 0.05 was considered to be 
significant.
RESULTS
The subjects of this study were 
thyroid enlargement patients who 
underwent thyroidectomy at Dr. Sardjito 
General Hospital, Yogyakarta. Based on 
the results of physical and adjunctive 
examinations obtained from 2015 to 
2017, patients with advanced stage 
thyroid carcinoma (stage III and IV) 
were included as case group and early 
stage (stage I and II) carcinoma patients 
were included as controls. There were 
33 patients diagnosed as advanced stage 
(stage III and IV) carcinoma and 33 
patients diagnosed as early stage (stage 
I and II) carcinoma. Histopathological 
examination of thyroid tissue after 
thyroidectomy was performed in the 
Department of Anatomical Pathology, 
Faculty of Medicine, Public Health and 
Nursing, Universitas Gadjah Mada/Dr. 
Sardjito General Hospital, Yogyakarta.
Characteristics of the subjects of 
this study include gender, age, and 
histopathology, is presented in TABLE 1.
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TABLE 1. Characteristics of research subjects
Characteristic Stage I and II[n (%)]
Stage III and IV
[n (%)]
Total
[n (%)] p
Sex
•	 Male 10 (30.3) 6 (18.2) 16 (24.2)
0.389
•	Female 23 (69.7) 27 (81.8) 50 (75.8)
Age
•	< 45 years old 20 (60.6) 0 (0.0) 20 (30.3)
0.001
•	 ≥ 45 years old 13 (39.4) 33 (100) 46 (69.7)
Histopathological
•	Papillary carcinoma 31 (93.9) 27 (81.8) 58 (87.9)
0.324
•	Follicular carcinoma 2 (6.1) 3 (9.1) 5 (7.6)
•	Undifferentiated 0 (0.0) 2 (6.1) 2 (3.0)
•	Hurtle cell carcinoma 0 (0.0) 1 (3.0) 1 (1.5)
There was no statistically significant 
difference (p=0.389) in sex distribution 
group sample between case and control 
groups (TABLE 1). The results of this 
study were similar to Haymart et al.6 
which obtained 80.7% of female thyroid 
enlargement patients and 19.3% of male 
with the ratio between femaleand male 
was 4.2:1. In addition, Boelaert et al.7 
reported the ratio between male and 
female was 8:1.
The greatest age frequency in the age 
group ≥45 were 46 (69.7%) people (TABLE 
3). By Fisher’s analysis exact test was 
found statistically significant difference 
in age between case group and control 
group (p= 0.001). This result is similar to 
Haymart et al.6 study, the age frequency 
of patients with the greatest thyroid 
enlargement is 45-50 years. Boelaert et 
al.7 reported that the peak incidence of 
patients with thyroid enlargement was 
48-50 years.
All patients with undifferentiated 
carcinoma histopathology were present 
in the case group (stage III and IV). A 
retrospective cohort studies conducted 
in the United States reported that 
distribution of histologic categories 
of thyroid cancer i.e. 88% papillary 
carcinoma, 9% follicular carcinoma and 
3% were poorly differentiated.8
The main outcome in this study was 
to evaluate the relationship between TSH 
levels and stage of thyroid carcinoma. 
High and low levels of TSH are 
determined based on the cut-off point 
of TSH levels obtained through receiver 
operating characteristic (ROC) curve 
analysis (FIGURE 1). The cut-off point 
TSH level based on receiver operating 
characteristic analysis curve was 1.27 
mIU/L with a sensitivity value of 0.727 
(72.7%) and a specificity value of 0.788 
(78.8%). Value area under the curve 
(AUC) 0.826 with p value = 0.001. Based 
on the cut of point value, TSH levels can 
be categorized as low TSH levels when 
<1.27 mIU/L and high TSH levels when ≥ 
1.27 mIU/L.
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FIGURE 1. Receiver operating characteristic (ROC) curve 
analysis of TSH
TABLE 2. Analysis of TSH levels on case and control groups
TSH level Stage I and II[n (%)]
Stage III and IV
[n (%)] p OR (95% CI)
Low TSH 26 (78.8) 9 (27.3)
0.001 9.9 (3.19-30.15)
High TSH 7 (21.2) 24 (72.7)
TABLE 2 shows that there was 
significantly difference between the 
TSH levels of the case and control 
groups by using cut off  1.27 m IU/ L 
(p = 0.001;OR: 9.9; 95% CI: 3.19-30.15). 
Thyroid enlargement patients with high 
TSH levels were at 9.9 times more likely 
to have advanced stage (stage III and IV) 
than patients with thyroid carcinoma 
with low TSH levels.
TABLE 3. Logistic regression analysis contribution 
independent variables
Variable β p OR 95%CI
TSH 2.94 0.009 18.93 2.09-171.30
Age 0.19 0.001 1.21 1.09-1.34
Sex 1.09 0.343 2.96 0.31-27.93
cut of point
1.27  
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TABLE 3 show the logistic regression 
analysis was done to determine the 
contribution of variable to the stage 
of thyroid carcinoma. Result of this 
study showed that TSH and age were 
significantly play a role in the stage of 
thyroid carcinoma, with p value of 0.009 
(OR: 18.9; 95% CI: 2.09-171.3) and 0.001 
(OR: 1.21; 95% CI: 1.09-1.34) respectively, 
while sex was not significantly play role 
(p = 0.343; OR: 2.96; 95%CI: 0.31-27.93). 
Gul et al.9 reported multivariate analysis 
of the variables that affect the thyroid 
malignancy. These variables included 
nodule type and TSH levels, free T3 
and free T4. This study did not directly 
determine the association of TSH levels 
with nodule types. It was concluded that 
TSH is an independent risk factor for 
thyroid malignancy separate from the 
nodule type.
DISCUSSION
TSH is a hormone that plays a 
role in stimulating the occurrence of 
hormone synthesis in the thyroid gland. 
TSH is one of four hormones produced 
by the anterior pituitary gland, with 
a molecular weight of about 26,000-
28,000 daltons. TSH production occurs 
by stimulation of thyrotropin releasing 
hormone (TRH), produced by the 
hypothalamus which then stimulates 
the pituitary gland to produce TSH. 
Under normal circumstances, levels of 
TSH present in the body range from 0.5-
5 mIU/L. Patients with euthyroid have 
levels of 1 mIU/L TSH.10-12
The incidence of thyroid carcinoma 
has tripled in the last three decades with 
increasing demographics and access to 
health care, resulting in more diagnosis 
being enforced. The mortality rate of 
thyroid carcinoma is relatively stable 
over this time period.13 The incidence 
of these carcinomas may be familial, 
either self-occurring or associated 
with Gardner’s syndrome (familial 
adenomatous polyposis). Radiation 
exposure especially during childhood 
is associated with thyroid papillary 
carcinoma. Tumors generally appear 
after a latent phase between 10-20 years. 
Increased incidence of thyroid papillary 
carcinoma is elevated in patients 
suffering from Hashimoto’s thyroiditis 
(chronic lymphocytic thyroiditis). But the 
incidence of this carcinoma in nodules 
was found in patients with Hashimoto’s 
thyroiditis and patients with the same 
normal thyroid.14
In differentiated thyroid carcinomas 
the value of TSH usually depends on the 
severity of the cancer. Almost all patients 
are expected to be around 0.1 - 0.5 mIU/L. 
Then performed thyroid function tests 
and Tg, 8 weeks postoperatively.15,16 If 
not detected Tg, do the examination 
6 months later in the form of neck 
examination and thyroid function 
examination. The examination was 
continued 1 year later with scan and Tg. 
When the scan is negative and Tg <2 ng/
mL, followed by 6 months interval for 
physical examination, thyroid function, 
Tg and ultrasound. After that monitoring 
was done 5 years later and there after 
followed annually.12,17
Risk factors associated with thyroid 
carcinoma include radiation exposure. 
The type of thyroid carcinoma associated 
with radiation exposure is papillary 
carcinoma. Specific radiation of the 
thyroid gland (thyroid ablation therapy 
with I131) or high-dose external-beam 
radiation therapy does not increase 
the risk of incident papillary thyroid 
carcinoma. At this dose of therapy most 
of the exposed cells will die. Populations 
with low iodine diarrhea are associated 
with the incidence of follicular and 
anaplastic carcinomas.1
Papillary carcinoma is a type of 
tumor with relatively slow growth. This 
tumor originates from the follicular cells 
that produce T4 and Tg in the thyroid 
gland. These cells are highly sensitive to 
TSH and take-up iodine. This provides 
a diagnostic and therapeutic value for 
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the treatment of residual disease and 
recurrence, after surgical treatment.18 
Follicular carcinoma is the second most 
common malignancy after thyroid 
papillary carcinoma. This cancer covers 
10% of all thyroid malignancies. This 
carcinoma shows an increased incidence 
in areas with low iodine intake. As with 
thyroid papillary carcinoma, thyroid 
solid carcinoma occurs more in females 
than males, with a ratio of 3:1.14,18
Patients with thyroid follicular 
carcinoma possess older age 
characteristics compared with patients 
suffering from thyroid papillary 
carcinoma in general. The average 
age is the 4th and 5th decades. Thyroid 
follicular carcinoma develops from 
thyroid follicular cells. These neoplasm 
cells depend on TSH, or are said to be 
sensitive to TSH, absorbing iodine and 
producing Tg.18
The signs and symptoms of thyroid 
carcinoma on clinical examination 
manifest as thyroid nodules, usually 
solid, painless, palpable. These nodules 
are often found on palpation of the 
neck. On physical examination palpable 
nodules usually in patients older than 
60 years or younger than 30 years. If 
the nodule is found in men, the risk of 
malignancy will be higher. In thyroid 
malignancy is often found rapid growth 
of nodules, although usually does not 
feel pain. If any sudden onset of pain 
may be associated with benign lesions of 
the thyroid such as: thyroid bleeding or 
acute thyroiditis.1,14
There are no symptoms that are 
typical for thyroid cancer, patients 
generally come with a painless lump in 
the neck. Anamnesis in patients with 
thyroid carcinoma most patients come 
with complaints of a lump on the anterior 
neck. Lumps caused by malignancy need 
to know risk factors such as; radiation 
history, family history, geography and 
settlement environment. Rapid growth 
with emphasis on surrounding organs 
or tissues can be a marker. In anaplastic 
type, growth is usually very rapid and 
followed by pain especially in elderly 
patients followed by changes in sound, 
difficulty swallowing and shortness of 
breath as a sign of tissue invasion or 
surrounding organs (recurrent nerves, 
esophagus and trachea).15
Investigations performed according 
to the guidelines of the UK Association 
of Thyroid Cancer (United Kingdom), 
are advised to perform thyroid function 
tests (TFTs) first in patients with thyroid 
nodules. The results of these checks are 
used to determine the intended referrals. 
If the euthyroid with suspected thyroid 
nodules are malignant, then referred to 
the cancer handling team. A hypothyroid 
and hyperthyroid state is not necessarily 
a malignancy, as differentiated cancer 
cells also have the ability to capture 
iodide and produce Tg. In some cases 
differentiated thyroid cancers have been 
reported thyrotoxicotic conditions.2,15,16 
Examination of thyroid gland function 
includes examination of levels of TSH, T4, 
T3, Tg, and calcitonin. Examination of Tg 
levels is used to evaluate the outcome of a 
therapy and the occurrence of recurrence 
in patients with thyroid cancer. 
Calcitonin may be a marker of medullary 
thyroid cancer, where laboratory tests 
are performed when anamnesis is found 
to have a family history and may be a 
routine examination.2,16
According to Zhang et al.19 diagnosis 
and management of differentiated 
thyroid carcinoma based on the 
American Thyroid Association guidelines 
in 2009, Bethesda’s system for thyroid 
cytopathology classification as well 
as current examination of molecular 
cytology with fine needle aspiration 
(FNA). Any symptomatic thyroid lump 
should be examined for TSH and thyroid 
ultrasound. Uptake thyroid examination 
is performed after TSH examination. 
Patients with hyperfunction nodules are 
referred to endocrine experts and not 
recommended for FNAs.
Thyroid carcinoma is the most 
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frequent endocrine neoplasm and 
mutation at the frequent thyrotropin 
receptor (TSHR). Some theories explain 
the process of carcinogenesis of thyroid 
carcinoma. Several theories are related 
to the role of TSH in the process of 
carcinogenesis and its progression. 
Several genes and structural proteins are 
involved in the TSHR mutation. Theories 
include cancer stem cell theory and 
classical theory. TSHR changes in thyroid 
cancer that play a role in the process of 
thyroid carcinogenesis associated with 
genetic instability during evolution. 
However the presence of functional 
TSHR is utilized in therapy. Epigenetic 
concepts also play a role in this process.20
TSH will induce the occurrence 
of cancer along with other growth 
factors. Chronic stimulation of TSH is 
an important carcinogenesis factor. The 
role of TSH receptors and TSH receptor 
mutations is known to play a role in the 
incidence of thyroid carcinoma. Genetic 
change is a risk factor for malignant 
growth in the thyroid.6  TSH activates the 
transmembrane-G protein receptor on 
the surface of follicle cell, and induces 
the production of intracellular cyclic 
AMP (cAMP). This process is carried out 
by the enzyme adenylate cyclase. The 
cAMP molecule will stimulate the cAMP-
dependent kinase A (PKA) protein, which 
will phosphorylate the cytoplasmic 
proteins and target proteins in the cell 
nucleus.21
The determination of the thyroid 
stage adheres to the TNM system, 
determined by primary tumor (T), 
lymph node metastasis (N), and distant 
metastasis. The higher levels of TSH are 
associated with the higher stage of thyroid 
cancer. Based on these data above serum 
TSH levels have an important role in 
the growth and development of thyroid 
carcinoma. TSH has been recognized as 
a growth factor of nodules in the thyroid, 
and suppression of TSH levels by giving 
exogenous thyroid hormone will inhibit 
the growth of existing nodules and 
inhibit the growth of new nodules.7
Ongoing TSH stimulation can change 
slowly differentiated thyroid carcinomas 
that grow rapidly and metastasize. 
Increased levels of TSH will increase the 
growth of thyroid carcinoma and TSH 
suppression therapy will decrease the 
size and decrease the rate of recurrence 
of differentiated thyroid carcinomas.22,23 
Differentiated thyroid tumors express 
TSH receptors in the plasma membrane. 
TSH will increase adenylate-cyclase 
activity which will increase cAMP 
production and cell growth through TSH 
receptors on in vitro examination.6,7
TSH is the main regulator of thyroid 
hormone production by follicular cells 
of the thyroid gland. Although TSH is 
not the only growth factor in thyroid 
tumors, TSH has an important role in 
the network of signals that modulate the 
growth of thyroid gland cells and their 
function. TSH has a role not only in the 
control of differentiation functions such 
as expression of thyroid-specific genes, 
but also regulates expression of growth 
factors and receptors.24 These growth 
factors and receptors include: epidermal 
growth factor receptor, insulin-like 
growth factor-1-dependent signal, and 
insulin. TSH has also been reported as 
a mitogen in the proliferation of thyroid 
carcinoma cells. All papillary and 
follicular thyroid carcinomas express 
TSH receptor at varying amounts.19,24,25
The state of thyroid function of the 
thyroid is not affected by TSH levels 
called autonomic thyroid function 
(TSH <0.4 μIU/mL) is associated with 
a reduced risk of papillary thyroid 
carcinoma. Some studies support higher 
levels of TSH, although still within the 
normal range, associated with thyroid 
cancer in patients with thyroid gland 
enlargement.26  The study in the number 
of research subjects 247, assessed the 
association of TSH levels and extension 
of extrathyroidal tumors and tumor size. 
This study concluded that there was 
a significant difference mean of TSH 
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level between subjects with extrathyroid 
extension compared with subjects without 
extension of extrathyroid with different 
grade of TSH 3.59 ( p= 0.004). In the same 
study, there was no significant difference 
in TSH levels between thyroid carcinoma 
with tumor size >4cm compared to <4cm 
with mean difference value of TSH level 
0.17 (p = 0.89).6
The prognosis of patients with 
differentiated thyroid carcinomas 
depends on the staging and therapy 
given. The choice of therapy is 
determined by staging of thyroid 
carcinoma. Some patients with higher 
stages require additional therapy such 
as neck dissection or ablation therapy. 
In this system, the stage depends on the 
patient’s age. Patients over the age of 45 
will have a higher relative stage than 
patients under 45 years of age at the time 
of diagnosis. The 5-year survival rate 
was 99% and the 10-year survival rate 
was 98%.12
CONCLUSION
There is a significant difference of 
TSH levels between early (stage I and 
II) and advanced stage carcinoma (stage 
III and IV). The TSH more than 1.27 
mIU/L can be considered as predictor for 
advance stage thyroid carcinoma.
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